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Neuroprotective natural antibodies to assemblies of
amyloidogenic peptides decrease with normal aging and
advancing Alzheimer's disease
Abstract
A number of distinct beta-amyloid (Abeta) variants or multimers have been implicated in Alzheimer's
disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural
Abeta-specific antibodies, but their diversity, abundance, and function in the general population remain
largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies
against known toxic Abeta and amyloidogenic non-Abeta species in plasma samples and cerebrospinal
fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent
against oligomeric assemblies of Abeta and pyroglutamate or oxidized residues, and IgGs specific for
oligomeric preparations of Abeta1-42 in particular declined with age and advancing AD. Most
individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant
forms of dementia (mutant Abeta, ABri, ADan) and IgGs isolated from plasma of AD patients or
healthy controls protected primary neurons from Abeta toxicity. Aged vervets showed similar patterns
of plasma IgG antibodies against amyloid peptides, and after immunization with Abeta the monkeys
developed high titers not only against Abeta peptides but also against ABri and ADan peptides. Our
findings support the concept of conformation-specific, cross-reactive antibodies that may protect against
amyloidogenic toxic peptides. If a therapeutic benefit of Abeta antibodies can be confirmed in AD
patients, stimulating the production of such neuroprotective antibodies or passively administering them
to the elderly population may provide a preventive measure toward AD.
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Abstracts 
A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer’s 
disease (AD) and antibodies recognizing such peptides are in clinical trials. Humans have natural 
Aβ-specific antibodies but their diversity, abundance, and function in the general population 
remain largely unknown. Here we demonstrate with peptide microarrays the presence of natural 
antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and 
cerebrospinal fluid (CSF) of AD patients and healthy controls aged 21-89 years. Antibody 
reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or 
oxidized residues and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined 
with age and advancing AD. Most individuals showed unexpected antibody reactivities against 
peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs 
isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ 
toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides 
and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides 
but also against ABri and ADan peptides. These finding support the concept that conformation-
specific, cross-reactive antibodies may protect against highly amyloidogenic toxic peptides. If a 
therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production 
of such neuroprotective antibodies or passively administering them to the elderly population may 
provide a preventive measure towards AD.
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\body 
Alzheimer’s disease (AD) is the most common cause of dementia affecting an estimated 5.3 
million individuals in the US alone. Deposits of β-amyloid peptide (Aβ) in extracellular plaques 
characterize the AD brain but soluble oligomeric Aβ species appear to be more neurotoxic than 
plaques and interfere with synaptic function (reviewed in (1)). Notably, most Aβ peptides 
isolated from AD brains are posttranslationally modified and truncated (2-6) and some are 
proposed to be oxidized (7, 8) or cross-linked at Tyr-10 (9). While the pathogenic consequences 
of these modifications need to be resolved, most of them can stabilize Aβ assemblies, interfere 
with proteolytic degradation, and increase Aβ toxicity in vitro (7, 8, 10).  
One line of defense against toxic Aβ species could be neutralizing antibodies. Stimulating the 
production of Aβ antibodies by active immunization with synthetic Aβ (11) or administering 
monoclonal Aβ antibodies (12, 13) reduced amyloid pathology and inflammation and improved 
cognitive function in mouse models of AD (14). In patients with mild to moderate AD active 
immunization appears to reduce plaque load (15) and in some patients production of Aβ 
antibodies correlated with attenuated cognitive decline (16). It has also been suggested that 
antibodies recognizing different domains (12, 13, 17) or conformations (18, 19) of Aβ may have 
different efficacy in humans. 
Interestingly, antibodies against Aβ occur naturally in blood and CSF in free form or in 
complex with Aβ, both in AD patients and healthy individuals (20-26). The titers of these 
antibodies are low and their origin and physiological or pathological role is unknown. Using 
crude methods Aβ antibody titers were found to be increased (22), decreased (23, 27, 28), or 
unchanged (21) in AD compared with healthy controls but a large scale analysis of Aβ antibody 
sub-specificities or changes in antibody repertoire with age or in response to Aβ vaccination has 
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not been described yet. Based on the presence of Aβ antibodies in normal plasma and the promise 
of therapeutic Aβ vaccines polyclonal intravenous immune globulins (IVIg) are being tested in 
clinical trials for the treatment of AD (25, 29).  
 
Results 
Plasma Aβ antibodies predominantly recognize high molecular weight assemblies in 
oligomeric preparations of Aβ1-42. To characterize the specificity of human plasma Aβ 
antibodies we isolated IgGs, and analyzed their reactivity to assemblies of Aβ1-42 peptides on 
Western blots. Some IgG samples reacted distinctively with a nonfibrillar Aβ assembly between 
55-78 kDa, reminiscent of the previously described 56kDa Aβ*56 (30) but the main reactivity in 
all samples was against entities larger than 210 kDa (Fig. 1A). The lack of binding to fibrillar Aβ 
preparations (Fig. 1A) indicates that most of the IgG antibodies are specific to smaller, 
potentially oligomeric conformations. As a control, the Aβ1-5 specific monoclonal antibody 3D6 
preferentially bound to highly abundant monomers, dimers and trimers in the oligomeric as well 
as in the fibrillar preparation and also to higher molecular weight assemblies in the fibrillar 
preparation on the same blot (Fig. 1B). We detected the high molecular weight assemblies in the 
oligomeric Aβ preparation only after repeated and isolated reprobing of the respective area of the 
membrane indicating that these larger assemblies are likely present at low levels (Fig. 1B). 
Atomic force microscopy confirmed the presence of predominantly fibrillar structures in fibrillar 
preparations (Fig. 1C) or nonfibrillar Aβ species in oligomeric preparations of Aβ1-42 (Fig. 1D). 
Together these data demonstrate the existence of highly specific IgG antibodies recognizing 
conformational epitopes in high molecular weight Aβ1-42 assemblies present in human plasma.  
 
Britschgi-manuscript-050609.doc  6 of 21 
Britschgi et al., Neuroprotective natural antibodies against amyloidogenic peptides in humans 
Plasma Aβ IgG antibodies are abundant and directed preferentially against oligomers and 
posttranslationally modified Aβ. To characterize and quantify the repertoire of natural 
antibodies against Aβ in human plasma on a large scale, we developed peptide microarrays 
containing various synthetic Aβ peptide variants, either non-aggregated or in different assembly 
states, as well as non-Aβ amyloidogenic peptides and controls (Table S1 and Fig. S1). To mimic 
some effects of oxidative stress in vitro we generated di-tyrosine cross-linked Aβ peptide species 
(CAPS) (9, 23) and confirmed oligomerization by Western blot analysis (data not shown). In a 
first experiment we measured relative Aβ antibody reactivities of the IgG class against 25 
different peptide preparations (Table S1) in plasma from 75 AD patients at various stages of 
disease and 36 healthy non-demented controls (NDC) (Table S2). Strikingly, antibodies 
recognizing higher order Aβ assemblies, including oligomer and fibrillar preparations, were more 
prevalent and up to 12-fold higher than the average reactivity against presumably non-aggregated 
preparations of Aβ1-40 and Aβ1-42 (Fig. 1E). No significant differences were observed between 
plasma from this mixed group of AD patients and NDC. Besides antibodies against 
conformational Aβ species we also discovered antibody reactivities against pyroglutamate Aβ 
variants, and curiously, against the peptide residue ABri3-34 (Fig. 1E).  
To replicate these findings in an independent sample set and to extend the panel of 
peptides, we screened plasma samples from an additional sample set of 55 AD patients and 62 
NDC subjects (Table S2) for antibodies against 74 different peptide preparations and controls 
(Table S1 and Fig. 1F, G). We confirmed that IgG reactivities against Aβ assemblies were 
generally higher than reactivities against non-aggregated Aβ (Fig. 1F). Although IgG titers to 
oligomeric preparations of Aβ1-42 (Fig. 1H) and other peptides (Fig. S2A, and data not shown) 
are relatively low, they were 2- to 4-fold higher than IgM reactivities within the same plasma 
sample (Fig. 1I) and for certain peptides up to 86-fold higher (Fig. S2A, B). These antibody titers 
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are also consistent with peptide array-based measurements of IgGs reactive to Aβ and myelin 
proteins in patients with multiple sclerosis (31), and support the concept of a circulating pool of 
self-reactive IgG antibodies in the general population (32, 33). 
Interestingly, most plasma samples had relatively high IgG antibody reactivity against 
posttranslationally modified peptides. For example, IgGs against pyroglutamate variants 
Aβ3(pE)-42 or Aβ11(pE)-42 were up to 12-fold higher than those against Aβ11-42 or the 
average reactivities against Aβ1-40 and Aβ1-42 (Fig. 1J). Similarly, the pyroglutamate form of 
Bri1(pE)-6 elicited a 26-fold higher reactivity than Bri1-6 (Fig. S2C). Oxidative modification of 
Aβ peptide as present in Aβ29-M35(MetSox) (Fig. 1K) or Aβ1-42 (Ox) (Fig. S2D) led to a 
prominent increase in IgG binding compared with the median IgG reactivity to non-aggregated 
Aβ1-40 and Aβ1-42. In contrast, antibody reactivities against control peptides APLP1(559-580), 
APLP2(662-686), or human Amylin1-37 were similar to reactivities against non-aggregated Aβ1-
40 or Aβ1-42 peptides (Fig. 1F). 
 
General elder population carries relatively high antibody reactivity against amyloidogenic 
peptides unique to autosomal dominant dementias. Of particular interest in the first 
experiment was the increased antibody reactivity against mutant Aβ peptides that are found 
exclusively in different familial forms of AD or against the peptide residue ABri3-34 (Fig. 1E), a 
putative fragment of an amyloidogenic peptide uniquely present in patients with familial British 
dementia (34). Consistent with the first experiment, relative antibody reactivities to mutant forms 
of Aβ1-40 or Aβ1-42 were several-fold increased compared to median reactivity for non-
aggregated preparations of Aβ1-40 or Aβ1-42 (Fig. 1G), and 15.2-fold higher for Aβ1-55 (Fig. 
1G). We observed relatively high antibody reactivities against full-length ABri and measured 
similar IgG titers for ADan (Fig. 1G), both peptides being mutant amyloidogenic non-Aβ 
Britschgi-manuscript-050609.doc  8 of 21 
Britschgi et al., Neuroprotective natural antibodies against amyloidogenic peptides in humans 
peptides present exclusively either in British (34) or Danish dementia (35). Oligomer 
preparations and posttranslationally modified residues or artificial variants of same peptides 
typically elicited even higher reactivities, e.g. relative reactivity against an oligomeric preparation 
of artificial mutant Bri16-23(A16K/V17K) was the strongest observed in our study (Fig. 1G). 
Electron microscopy confirmed in this preparation the presence of structures reminiscent of 
previously described globular or annular assemblies of Aβ and other amyloidogenic peptides (36, 
37) but no assemblies were detected in freshly dissolved peptide (Fig. 1 L, M). Together, these 
data from two independent sample sets demonstrate for the first time the abundance of a diverse 
IgG repertoire in human plasma recognizing higher order assemblies of Aβ peptides, 
pyroglutamate Aβ, oxidized Aβ, and mutant Bri peptide residues. The presence of antibodies in 
individuals who are not carriers of a mutation for familial dementia supports the existence of 
cross-reactive conformation-specific antibodies. 
 
Reduced antibody reactivities against oligomeric Aβ1-42 assemblies in advanced AD and in 
normal aging. Although no overall differences in Aβ or other peptide antibody reactivities were 
observed between a diverse group of AD patients and NDC, patients in sample set 1 with 
moderate to severe AD (mini-mental state exam score, MMSE scores ≤ 19) had significantly 
lower levels of antibody reactivities against oligomeric preparations of Aβ1-42 than patients with 
mild disease (MMSE scores ≥ 20) (Fig. 2A). A similar group difference was found in sample set 
2, although it did not reach significance (Fig. 2B), possibly due to the low number of patients 
with severe disease (Table S2). No group difference was detected for antibodies recognizing 
non-aggregated Aβ, control antigens ‘pneumococcal vaccine polyvalent’ and C. albicans extract 
(data not shown), arguing against a general age-related decline in antibody titers in our sample 
sets. Also, ApoE4 carriers did not differ from non-carriers in their immunoreactivity with all 
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tested antigens (data not shown). 
To determine antibody reactivities at different ages we screened plasma samples from a third 
set of samples collected from 66 healthy, non-demented females ages 21 to 85 years old (Table 
S2 and Fig. S3) and found six antibody reactivities that were on average 45-65% higher in 
plasma from the youngest (21-44 years) compared with the oldest (≥ 70 years) age groups (Fig. 
S4A-F). Total IgG levels and other reactivities did not change (Fig. S4G-L and data not shown), 
and only reactivity to pneumococcal vaccine increased with age (Fig. S4M) again arguing against 
a general loss in overall immunity in the elderly studied here. Using linear regression methods we 
found eight antibody reactivities that were strongest associated with age as illustrated in a node 
map generated by an unsupervised cluster algorithm to arrange all samples based on similarity of 
antibody reactivities (Fig. 2C). Antibody reactivities against some of these peptides showed 
significant inverse correlations with age (Fig. S4N, O). A comparison of reactivities of free Aβ 
antibodies with pH 3.5 immune complex-dissociated Aβ antibodies (38) by ELISA showed that 
low pH treatment  increased antibody reactivities against oligomeric Aβ in all tested plasma 
samples 2 to 7.4-fold (Fig. 2D, mean 3.9 ± 1.1 standard deviation) compared with untreated 
samples. This is similar to reports in human serum and IvIg preparations (25, 26). The percentage 
of free antibodies out of the total pool recognizing Aβ1-42 oligomers ranged from 13% to 50% 
but was not associated with age or AD (mean 27.7% ± 7.8% standard deviation; Fig. S5). 
Together, these data indicate that relative plasma antibody reactivities against several 
amyloidogenic Aβ mutant and non-Aβ peptides and in particular to oligomeric Aβ1-42 are 
reduced with age. 
 
Plasma IgG reactivity is similar in CSF and protects primary neurons from Aβ toxicity. To 
investigate whether any of the antibodies detected in the periphery may have access to the CNS 
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we measured antibody titers in CSF samples from healthy normal controls (n = 16, aged 24-83 
years) and patients with mild AD (n = 6, aged 70-84 years) using peptide arrays. Average 
reactivities in CSF were about 30 to 230 times lower in CSF than in plasma but a similar 
repertoire of IgG antibodies was seen. Similar to plasma, highest titers were observed for 
oligomeric preparations of Aβ1-42, pyroglutamate modified Aβ peptides, and mutant variants of 
Aβ, ABri and ADan (Fig. 3A). There was no significant difference in reactivities in the analyzed 
sample groups and IgM was not detectable (data not shown). 
To assess the potential physiological relevance of natural Aβ antibodies we tested the 
protective potential of IgGs against Aβ toxicity. IgGs purified from three plasma samples and 
acidified to release bound peptides (see above) were preincubated with oligomeric preparations 
of Aβ1-42 and this mix was added to primary hippocampal neurons from E16 mice. All three IgG 
preparations significantly reduced cell death (Fig. 3B) and increased cell viability (Fig. 3C) to an 
equal or greater extent than monoclonal antibodies to Aβ, consistent with similar experiments 
done with IvIg (25). 
 
Immunization with Aβ peptides amplifies immune response to Aβ, ABri, and ADan 
peptides in non-human primates. To further study the in vivo relevance of natural antibodies to 
amyloidogenic peptides, we measured immunoreactivity in plasma of a sub-cohort of vervet 
monkeys from a previously published study (39). Aged animals can develop features of AD 
including cerebral amyloid plaques that stain positive with anti-human Aβ antibodies (39) 
indicating high homology between human and vervet Aβ similar to other non-human primates 
(40). Immunization with a cocktail of human Aβ1-40 and Aβ1-42 almost entirely cleared 
cerebral Aβ plaques (39). While standard ELISA methods detected miniscule levels of Aβ1-40 
antibodies in non-immunized vervets (39), using our peptide arrays, we were able to measure 
Britschgi-manuscript-050609.doc  11 of 21 
Britschgi et al., Neuroprotective natural antibodies against amyloidogenic peptides in humans 
reactivities to non-aggregated and oligomeric Aβ preparations as well as to Aβ3(pE)-42 species 
comparable to what we detected in human plasma (Fig. S6A-C). At the end of the study, at 301 
days, control animals had unchanged or decreased titers to most of the tested peptides (Fig. 3D, 
Fig. S6B), while immunized vervets developed a 370-fold median increase (range of 80 to 
50000-fold) in IgG antibodies to full length Aβ preparations (Fig. 3E, Fig. S6D).  In support of 
earlier findings that immunization with Aβ was mainly targeting the peptide’s N-terminus (39) 
immunized vervets failed to develop a comparable immune response to Aβ33-42 (0.2 to 22-fold). 
Most importantly, and in likely support of their physiological relevance, immunized vervets 
significantly increased antibody levels to pyroglutamate modified Aβ (e.g. Aβ11(pE)-42), mutant 
Aβ (e.g. Aβ1-42(E22Q) Dutch), and the foreign peptides ABri and ADan (Fig. 3E, Fig. S6D). 
These data show that immunization with full-length Aβ not only increases immunity to select Aβ 
peptide species but also triggers the expansion of cross-reactive antibodies against other known 
toxic amyloidogenic peptides. 
 
Discussion 
This study presents the first large-scale characterization of naturally occurring antibodies 
against Aβ and related peptides in humans and non-human primates. Using immunoblots, ELISA 
and peptide glass arrays we demonstrate that plasma and CSF contain IgGs that are reactive 
against a broad range of amyloidogenic peptides including N-terminally pyroglutamate-modified 
or oxidized Aβ, and different oligomeric species of Aβ. We also detected various antibody 
reactivities against peptides unique to autosomal dominant dementias such as mutant Aβ, ABri 
and ADan supporting the existence of cross-reactive antibodies, which recognize conformational 
epitopes shared by known toxic amyloidogenic peptides. Unmasked IgGs protected primary 
neurons from Aβ toxicity pointing to a physiological relevance of these low titer antibodies. The 
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finding that immunization of vervet monkeys with (unmodified) Aβ peptides not only increased 
immunity to Aβ peptide species but also amplified the production of antibodies that react with 
pyroglutamate- modified Aβ, ABri and ADan further supports the in vivo importance of 
antibodies that are cross-reactive to known toxic amyloidogenic peptides. 
Studies in mice (22, 38, 41) and humans (20-22, 24-26) described natural antibodies against 
Aβ1-40 or Aβ1-42 before, without assessing their fine specificity or preference for specific 
assembly states in detail. Because the typical overnight coating of ELISA plates with Aβ 
resuspended in PBS is similar to the protocol for generating oligomeric Aβ species (42) it is 
likely that some of these previous studies measured antibodies against various mixtures of 
oligomeric and monomeric Aβ. The first study to specifically measure circulating natural human 
antibodies against Aβ oligomers used redox-modified cross-linked oligomeric species of Aβ 
(CAPS) and reported about 25% less reactivity in AD patients compared with healthy controls 
(23). Others described increased titers of antibodies specific for Aβ25-35 oligomers in mild to 
moderate stages of AD (43). Our large scale survey of antibody reactivities confirmed the 
existence of antibodies recognizing CAPS described by Moir et al. (23), although we could not 
find a significant decrease in AD patients. We also detected in general only low titers to non-
aggregated Aβ1-40 or Aβ1-42 and unmodified Aβ (Fig. 1) but higher reactivities for antibodies 
recognizing other oxidized or oligomeric assemblies of Aβ (Fig. 1J, K). 
Why would many of these antibodies, particularly those against oligomeric Aβ1-42, 
decreased with normal aging and more so with progression from mild to severe AD (Fig. 2A-C)? 
Cerebral Aβ appears to be in equilibrium with plasma Aβ (44) and it was proposed that CNS Aβ 
levels could be reduced by trapping the peptide in a “peripheral sink” (12, 45). Once in the 
periphery it is possible that Aβ specific IgGs form immune complexes more readily with Aβ in 
plasma from certain AD patients compared with NDC (26). This could be due to higher levels of 
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Aβ available for binding to antibodies or complement-mediated clearance of immune complexes 
(46, 47). Our data confirm that certain peripheral plasma Aβ antibodies are complexed (Fig. 2D) 
Alternatively, the reduction of certain Aβ antibodies with AD may represent a 'failed' immune 
response in AD, in line with recently described dysfunctional immune signaling pathways in the 
blood of AD patients (48). 
The function of natural plasma Aβ antibodies is unknown but immunization trials in AD 
mouse models, vervet monkeys, and AD patients suggest that Aβ-sequence or conformation-
specific antibodies are sufficient to induce the clearance of Aβ from the brain through a number 
of different pathways and that the fine specificity of these antibodies may affect their therapeutic 
efficacy (12, 13, 17-19, 39, 49). For example, Aβ antibodies isolated from human plasma are 
capable of binding to plaques and neurons in brain sections of AD patients (20) and AD mouse 
models (16) and such antibodies appear to facilitate the phagocytosis of Aβ by microglia in vivo 
(17, 50) or solubilize fibrillar amyloid directly (51). Here we show that unmasked IgGs are 
capable of neutralizing some of the toxic properties of Aβ1-42 in vitro (Fig. 3B, C). We also 
detected low levels of IgGs but not IgMs reactive to Aβ and other peptides in CSF (Fig. 3A) 
indicating that a small fraction of peripheral antibodies reaches the CNS which is consistent with 
findings in mice (44). 
What is the origin of these Aβ and amyloidogenic peptide specific antibodies? Without 
getting too much into the complexity of natural autoantibodies (32, 33) there are two main 
possibilities: the specific antigen triggers the expansion of antibodies, or cross-reactive epitopes, 
endogenous or foreign, provide the antigenic stimulus. In favor of the first possibility, no Aβ-
specific antibodies could be detected in wild-type mice (22, 38), but they are present in APP 
transgenic mice where Aβ antibody titers correlated inversely with plaque pathology (41). It is 
also possible that posttranslationally modified and toxic Aβ triggers the production and 
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maturation of at least some antibodies. Pyroglutamate variant Aβ3(pE)-42 and to a lesser extent 
Aβ11(pE)-42 are a predominant Aβ species in AD plaques (2-4, 10, 52), and together with other 
N- and C-terminally truncated Aβ species, they are also formed in plaque-free brains of healthy 
individuals aged at least 70 years (6). Moreover, because Aβ3(pE)-42 forms aggregation seeds 
250-fold faster than unmodified Aβ (53) it may trigger antibody responses at very low 
concentrations long before pathological changes are observed in the brain. Indeed, human plasma 
in general showed high reactivity against pyroglutamate-modified peptides such as Aβ3(pE)-42, 
Aβ11(pE)-42, but only low reactivity against unmodified Aβ11-42 (Fig. 1J and S2C).  
More likely, however, unknown epitopes trigger the formation of cross-reactive IgG 
antibodies with reactivities against Aβ and related amyloidogenic peptides. The strongest support 
for this idea comes from the observation that healthy humans have antibodies against ABri1-34 
and ADan1-34 (Fig. 1E, G, 3A, and S3B), which are exclusively generated as a result of two 
separate mutations in the ITM2B gene in familial British (34) or Danish (35) dementia, 
respectively. We also found in plasma and CSF increased IgG immunoreactivity to familial AD-
associated mutant forms of Aβ peptides which are not present in the general population (Fig. 1E, 
G, 3A, and S3B). In addition, the observation that some of the antibodies against amyloidogenic 
peptides are at their highest levels in young, presumably pathology free individuals (Fig. 2C and 
S4), seems counterintuitive to an immune response triggered by disease-associated Aβ peptides. 
In fact, our findings do not support studies describing a general increase in autoantibody titers to 
endogenous antigens with age in humans (54), but may be more consistent with an age-related 
decrease of immune response to exogenous antigens (54) that mimic amyloidogenic peptides. In 
support of this, new evidence in mice indicates that at least some Aβ antibodies may be induced 
by a peptide sequence in the common potato virus Y (PVY) homologous to the N-terminus of Aβ 
(55). Antibodies against PVY were also isolated in a screen of a human synthetic phage-antibody 
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library (56), but it remains unknown whether the general population develops a specific immune 
response to PVY with cross-reactivity to Aβ. 
No matter what their origin, antibodies against many of the amyloid peptides we measured 
can be dramatically expanded upon immunization with Aβ in vervets (Fig. 3E). What’s more, 
even though unmodified Aβ1-40 and Aβ1-42 was used in the immunization paradigm, antibodies 
against pyroglutamate modified Aβ3(pE)-42 and Aβ11(pE)-42 or against ABri or ADan peptides 
were also strongly expanded, again supporting the concept of crossreactive tertiary epitopes 
shared among amyloidogenic peptides (57). Since immunization of the vervets led to an almost 
complete clearance of cerebral Aβ deposits (39) it becomes interesting to determine which types 
of antibodies are most potent in clearing Aβ. While we have no comparable data from human 
clinical trials, it is reasonable to assume that active immunization with Aβ peptides would trigger 
a similar expansion of a repertoire of amyloidogenic peptide specific antibodies in humans 
possibly leading to cognitive improvement as well. If individual or groups of antibodies against 
e.g. pyroglutamate modified or tertiary structures of Aβ turn out to have better therapeutic 
benefits, active immunization with such structures may provide a better and more economic 
approach than treatment with a single, potentially mono-specific antibody. 
In summary, our findings demonstrate that naturally occurring antibodies specific for known 
toxic Aβ and amyloidogenic non-Aβ species are abundant in healthy humans and some decrease 
with age and advancing AD. Plasma IgGs are capable of reducing part of Aβ’s neurotoxicity but 
more studies are necessary to understand the role of these antibodies in vivo. If a therapeutic 
benefit of Aβ antibodies can be confirmed, stimulating production of conformation-specific Aβ 
antibodies or passively administering the most efficacious ones to the elderly population may 
provide a preventive measure towards AD. We speculate that certain non-self amyloidogenic 
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peptides might be more powerful than Aβ preparations in inducing therapeutic immune responses 
in AD and carry potentially a lower risk to trigger autoimmune inflammation.  
 
Materials and Methods 
Detailed technical descriptions are provided in SI Methods 
Plasma and CSF samples. A total of 252 archived human EDTA plasma samples and 22 CSF 
samples were obtained from academic centers specialized in neurological or neurodegenerative 
diseases (Table S2). Informed consent was obtained from all human subjects in accordance with 
IRB-approved protocols. Vervet plasma samples came from a previously published Aβ 
immunization study (39) (Table S2). One control animal was not part of the original study. The 
animals were housed at the Caribbean Primate Laboratories, Behavioral Science Foundation 
(BSF) in St. Kitts, Eastern Caribbean, which is a fully accredited biomedical research facility 
with approvals from the Canadian Council for Animal Care (CCAC) and the USPHS. 
 
Peptides and proteins. We obtained reverse-phase HPLC purified peptides from different 
sources (Table S1). Preparation of Aβ assemblies was done as described earlier (23, 42). Some 
preparations were analyzed by atomic force or electron microscopy (see SI Methods). Candida 
albicans extract, pneumococcal vaccine, polyvalent, monoclonal antibodies recognizing human 
IgG (H+L) or IgG/IgM, and Cy3-labeld BSA were used as controls. 
 
Antigen arrays. Antigen microarrays (Table S1 and Fig. S1C, D) were printed in batches of up 
to 200 slides with a custom built robotic microarrayer by contact printing onto reactive epoxide-
coated glass slides in an ordered array. Glass slides were probed with diluted sample or specific 
antibodies and data were extracted as described (58).  
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Statistical analyses. Most statistical analyses were done in GraphPad Prism 5.0 with p ≤ 0.05 
considered significant (Mann-Whitney U test, parametric or non-parametric one-way ANOVA, 
and appropriate post hoc test). Multivariate comparison analysis between youngest and oldest age 
groups and linear regression analysis of age with z-scored antibody reactivities was done with the 
software package Significance Analysis of Microarray (SAM (59)) and 0% false discovery rate 
was considered significant. Unsupervised cluster analysis was done in Cluster 3.0 (60) and a node 
map was generated in Java TreeView (61). Penalized linear regression models were calculated by 
the regularization and variable selection method elastic net (62). 
 
Antigen-antibody dissociation and ELISA. Dissociation of immune complexes in plasma and 
detection by indirect ELISA was done at pH 3.5 as described with modifications (25, 38).  
 
Immunoblots with human IgGs and Aβ-specific antibody. Preparations of Aβ1-42 peptides 
were run on 10-20% Trice gels (Invitrogen), transferred to 0.2 μm nitrocellulose membranes, and 
detected with isolated and biotinylated human IgGs or Aβ1-5 specific mouse monoclonal 
antibody (3D6) by standard Western blot procedures. 
 
In vitro Aβ neurotoxicity assay. Hippocampal neuronal cultures from embryonic day 15-16 
CF1 mice were treated on day six with 2 μM Aβ oligomers in the presence or absence of antigen-
dissociated and purified human IgGs or indicated monoclonal antibodies. After 3 days, cell death 
or viability was measured with standard LDH release and tetrazolium salt-based assays. 
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Figure Legends 
Figure 1. Human plasma IgGs preferentially recognize oligomeric and postranslationally modified 
Aβ. (A) Membranes with fibrillar (f) and oligomeric (o) preparations of 2 μg Aβ1-42 were probed with 
biotinylated human IgG fractions isolated from plasma of two non-demented controls (NDC) and two AD 
patients. Bound IgGs were detected by HRP-tagged avidin. (B) In parallel experiments membranes were 
probed with Aβ1-5-specific mAb 3D6 (0.5 µg/ml). Since 3D6 did not detect the high molecular weight 
species of Aβ1-42 in the oligomeric preparation after the first probing, the lane with the fibrillar preparation 
was cut off and the truncated membrane strip containing oligomeric Aβ1-42 above 17 kDa was reprobed 
with fresh antibody. This was repeated one more time after cutting the strip above 55 kDa. (C) Fibrillar and 
(D) oligomeric preparations of Aβ1-42 analyzed by atomic force microscopy (5 nm total z-range). (E-G) 
Human IgG reactivities against peptide preparations were measured with antigen microarrays in plasma 
from AD patients and NDC in sample set 1 (E) and sample set 2 (F, G) (bars represent mean ± SEM). 
Names underlined with dashed lines are synthetic mutant peptides not present in vivo. No significant 
differences in antibody reactivities were observed between samples from AD patients and NDC for any 
antigen in both sample sets (Significance Analysis of Microarray). (H, I) Titration of plasma IgG (H) and 
IgM (I) reactivity to oligomeric Aβ1-42 in three samples. (J, K) Antibody reactivities against groups of 
peptides (closed symbols) compared to reactivities against control antigens (open symbols) in sample set 
2. Each dot represents median measurement for one plasma sample (log scale; mean reactivity; ***, P ≤ 
0.001; Mann-Whitney U test or Kruskal-Wallis one-way ANOVA followed by Dunn’s post hoc test). (L, M) 
Electron microscopy analysis of assembly status of non-aggregated (L) and oligomeric preparation (M) of 
Bri16-23(A16K/V17K). DFU, digital fluorescent units. 
 
Figure 2. Reactivity to oligomeric assemblies of Aβ peptides decline with progression of AD and 
together with other reactivities also decrease with age. (A, B) Average antibody reactivity for Aβ1-42 
oligomer preparations in AD patients with mild (MMSE score ≥ 20, orange dots) or moderate to severe 
stages (MMSE score ≤ 19, red dots) of the disease in sample set 1 (A) and sample set 2 (B) (mean 
reactivity; **P ≤ 0.01, Mann Whitney U test). Each dot represents median measurement for one plasma 
sample. (C) Unsupervised clustering of antibody reactivities that are significantly associated with age in 
healthy females (n = 66) ages 21-85 years (Significance Analysis of Microarray). Age of donors is 
indicated on the right of the node map as boxes with increasing intensities of purple for higher age. Color 
shades of the node map indicate higher (red) or lower (blue) antibody reactivity. (D) ELISA measurements 
for free (untreated) and total (immune complex dissociation at pH 3.5) antibody reactivity against 
oligomeric species of Aβ1-42 in randomly selected plasma samples of healthy individuals from different 
age groups (n = 11-15 samples per group) of sample set 3 and AD patients (n = 13) of sample set 2 
(mean; one-way ANOVA and Tukey’s post hoc test). DFU, digital fluorescent units; OD450, optical density 
at 450 nm. 
 
Figure 3. IgGs to Aβ are present in human CSF, protect neurons from Aβ toxicity in vitro, and are 
amplified together with ABri and ADan cross-reactive antibodies in an Aβ immunization paradigm. 
(A) IgG reactivity pattern in CSF of AD patients (≥70 y) and non-demented (NDC) young (24-48 y) and 
aged individuals (58-83 y) (bars represent means of median reactivities ± SEM). (B, C) Protective effect of 
human IgGs on primary mouse E16 neurons incubated with oligomeric preparation of Aβ1-42 was 
measured by (B) percent lactate dehydrogenase (LDH) release in dying cells and by (C) percent 
generation of intracellular formazan in surviving cells. Amount of water-soluble formazan produced by 
cells in culture medium alone was considered 100% survival (bars represent mean ± SEM of three 
experiments done in triplicates; symbols in scatter plot represent mean of one triplicate experiment; *P ≤ 
0.05, one-way ANOVA and Dunnett’s multiple comparison test with ‘no antibody’ as control). (D, E) Vervet 
monkeys were (D) left untreated or (E) immunized with a cocktail of Aβ1-40 and Aβ1-42 (39). 
Immunoreactivity at the end of the study (day 301) was divided by the baseline reactivity to individual 
peptides and result is presented as log fold change (bars represent median fold change of reactivity to a 
peptide for each individual animal). As expected, immunoreactivity to Aβ1-40 and Aβ1-42 peptides and 
oligomeric assemblies increase over several log ranges. Note the increase in reactivity to Aβ11(pE)-42, 
ABri, and ADan but the lack of increase to Aβ33-42. DFU, digital fluorescent units. 
